

Date 27 August 2026
Your Ref
Our Ref 11783

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing.

Question:

1. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Answer:

April 2026 - June 2026	
Medication	Patient Count
Benralizumab (Fasenra)	Information Unavailable
Depemokimab (Exdensur)	0
Dupilumab (Dupixent)	304
Mepolizumab (Nucala)	Information Unavailable
Omalizumab (Xolair)	100
Reslizumab (Cinqaero)	0
Tezepelumab (Tezspire)	Information Unavailable

Question:

2. How many patients were treated for **severe asthma, COPD, CRwNP** with the following medicines in the 3 months between the start of April 2026 and end of June 2026?
3. How many patients were treated for **Atopic Dermatitis** with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Answer:

I am advised that these questions are diagnosis specific and we do not collect this data in a centrally extractable format.

Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there

would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

4. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Answer:

Medication	April 2026 - June 2026		
	Respiratory departments	Dermatology departments	Other departments
Benralizumab (Fasenra)	Information Unavailable	0	Information Unavailable
Depemokimab (Exdensur)	0	0	0
Dupilumab (Dupixent)	29	268	Information Unavailable
Mepolizumab (Nucala)	Information Unavailable	0	Information Unavailable
Omalizumab (Xolair)	Information Unavailable	79	5<
Reslizumab (Cinqaero)	0	0	0
Tezepelumab (Tezspire)	Information Unavailable	0	Information Unavailable

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive